NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) posted its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to the consensus estimate of $11.18 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 773.82%. The firm's quarterly revenue was up 776.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) earnings per share. View Synergy Pharmaceuticals' Earnings History.

8 brokers have issued 1-year target prices for Synergy Pharmaceuticals' stock. Their forecasts range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' share price to reach $8.8125 in the next twelve months. This suggests a possible upside of 366.3% from the stock's current price. View Analyst Ratings for Synergy Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Synergy Pharmaceuticals saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 54,868,105 shares, a decrease of 12.8% from the June 15th total of 62,939,216 shares. Based on an average daily volume of 3,251,186 shares, the short-interest ratio is presently 16.9 days. Currently, 22.3% of the shares of the company are sold short. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN), ARMO Biosciences (ARMO), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Uniqure (QURE), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH) and Arrowhead Pharmaceuticals (ARWR).

Media headlines about SGYP stock have been trending positive recently, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a coverage optimism score of 0.28 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.15 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.89.

Synergy Pharmaceuticals has a market capitalization of $468.81 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]